Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between ...

Eli Lilly is grabbing investor attention thanks to sharp earnings and revenue growth projections, though its Zacks Rank ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Efsitora matched or exceeded A1C reductions seen with daily basal insulin across three trials, while orforglipron ...

Eli Lilly and Company (NYSE:LLY) was the only pharmaceutical company to make the list. The firm offers a dividend yield of 0.76% and has seen its stock has surged by nearly 2% year-to-date.

Eli Lilly shares, which entered Tuesday up roughly 5% this year, were down less than 1% in recent trading. With today's sharp gains, Verve stock has nearly doubled in 2025.

Indianapolis-based Eli Lilly announced its definitive agreement to acquire Verge, a gene-editing startup, for up to $1.3 billion at $10.50 a share -- a premium of 67.5% at last closing -- with the ...

Eli Lilly (LLY) is set to acquire Verve Therapeutics (VERV), sending Verve's stock skyrocketing. PureCycle Technologies (PCT) stock surges on the company's plans to grow its plastic recycling ...

Eli Lilly (LLY) is reportedly nearing a deal to acquire gene editing startup Verve Therapeutics (VERV) for up to $1.3 billion, the Financial Times reported.